Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients. (academic.oup.com)

Authors: Limaye AP … Haber B Journal: Clinical Infectious Diseases Published: 2026-02-25 DOI: https://doi.org/10.1093/cid/ciaf632